Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338146 | 0.83 | MAOB (0.39) | CHRM4ALOX5MAPK1BCHENPC1 | |
| SCHEMBL2683457 | 0.83 | MAOB (0.39) | CHRM4ALOX5MAPK1BCHENPC1 | |
| SCHEMBL2683456 | 0.83 | MAOB (0.39) | CHRM4ALOX5MAPK1BCHENPC1 | |
| SCHEMBL27488557 | 0.78 | CHRM4 (0.54) | CHRM4ALOX5MAPK1NPC1RAB9A | |
| SCHEMBL4601018 | 0.78 | CHRM4 (0.54) | CHRM4ALOX5MAPK1NPC1RAB9A | |
| SCHEMBL6625512 | 0.78 | CHRM4 (0.54) | CHRM4ALOX5MAPK1NPC1RAB9A | |
| SCHEMBL4602232 | 0.78 | CHRM4 (0.54) | CHRM4ALOX5MAPK1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4600885 | 0.77 | CHRM4 (0.53) | CHRM4ALOX5MAPK1NPC1RAB9A | |
| SCHEMBL2683449 | 0.72 | CHRM4 (0.42) | CHRM4ALOX5BCHENPC1RAB9A | |
| SCHEMBL2338156 | 0.72 | CHRM4 (0.42) | CHRM4ALOX5BCHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1863802-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1987834-A2 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-27 | — | — | US | disclosed |
| EP-1863802-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2006103273-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | REN, AGTR1, ACE | CHRM4 1015/4885ALOX5 4208/4885MAPK1 793/4885 |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | REN, AGTR1, ACE | CHRM4 554/4885ALOX5 4153/4885MAPK1 1275/4885 |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | CHRM4 2037/4885ALOX5 4669/4885MAPK1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.